About AusBiotech.

Dr Megan Baldwin is a seasoned biotechnology executive with over 25 years of experience in angiogenesis and the development of therapeutics for cancer and ophthalmic diseases. She was the Founder, Chief Innovation Officer, and Executive Director of Opthea Ltd, and served as the company’s CEO and Managing Director from 2014 to 2023.

During her time at Opthea, Dr Baldwin led the company’s evolution from a research-focused venture into a late-stage clinical enterprise, advancing its lead asset, OPT-302, from preclinical development through to global Phase 3 trials for wet age-related macular degeneration. Under her leadership, Opthea secured significant capital, including a dual listing on the Nasdaq and ASX exchanges.

In January 2025, Dr Baldwin was appointed an Independent Non-Executive Director of Race Oncology Ltd (ASX:RAC), where she brings deep strategic and scientific expertise in oncology drug development.

Earlier in her career, she held research and commercial roles at Genentech (now Roche), where she worked in the laboratory of angiogenesis pioneer Dr Napoleone Ferrara and later led corporate competitive intelligence initiatives in oncology.

Dr Baldwin holds a PhD in Medicine from the University of Melbourne, completed at the Ludwig Institute for Cancer Research. She is a member of the Australian Institute of Company Directors and currently serves on the Board of AusBiotech.

Dr Baldwin’s career reflects a long-standing commitment to scientific innovation and leadership in Australia’s biotechnology sector.

She is a member of the Australian Institute of Company Directors and an experienced company director having served on the Boards of both private and public companies.